We report that the level of intratumoral DAG determines the response of anti-BRAF/EGFR therapy in BRAFV600E-mutant mCRC, enriching our understanding of DAG’s regulation of tumor-targeted therapy. This evidence concerns the gene BRAF and neoplasm.